Arcutis Biotherapeutics Inc (ARQT)
8.60
-0.24
(-2.71%)
USD |
NASDAQ |
May 02, 16:00
8.60
0.00 (0.00%)
After-Hours: 20:00
Arcutis Biotherapeutics Cash from Operations (TTM): -247.06M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -247.06M |
September 30, 2023 | -261.88M |
June 30, 2023 | -285.59M |
March 31, 2023 | -281.08M |
December 31, 2022 | -257.72M |
September 30, 2022 | -238.36M |
June 30, 2022 | -211.55M |
March 31, 2022 | -185.40M |
December 31, 2021 | -174.63M |
Date | Value |
---|---|
September 30, 2021 | -155.49M |
June 30, 2021 | -148.30M |
March 31, 2021 | -138.23M |
December 31, 2020 | -113.03M |
September 30, 2020 | -97.26M |
June 30, 2020 | -74.29M |
March 31, 2020 | -56.77M |
December 31, 2019 | -42.84M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-285.59M
Minimum
Jun 2023
-42.84M
Maximum
Dec 2019
-174.67M
Average
-174.63M
Median
Dec 2021
Cash from Operations (TTM) Benchmarks
AdaptHealth Corp | 480.67M |
Puma Biotechnology Inc | 27.01M |
Adverum Biotechnologies Inc | -90.90M |
Apellis Pharmaceuticals Inc | -594.74M |
Karuna Therapeutics Inc (DELISTED) | -385.82M |